Company Develops Breast Cancer Return Test
October 22, 2010
October 20, 2010
WEST LAFAYETTE, Ind. - Connie Krabbe understands the fear and foreboding breast cancer survivors feel when visiting their physicians for post-treatment check-ups. Two of her four sisters died of metastatic cancer related to breast cancer, enduring bone, brain and ovarian cancer before succumbing to the disease in their early 50s.
"The original diagnosis was devastating, but the panic they felt during follow-up visits was even worse. It was agony to find a recurrence," said Krabbe, who is a retired insurance executive. "For me, it wasn't if the cancer would come back, it was when and would there be time to treat it."
According to the American Association of Cancer Research, breast cancer recurrence occurs in more than 20 percent of breast cancer survivors.
So the news that a cancer recurrence detection blood test developed by Matrix-Bio Inc has the potential to detect the recurrence of breast cancer a year in advance of currently available clinical diagnostic tests is something Krabbe applauds.
"Catching the recurrence of cancer early can make all the difference in the world. It can save lives," she said.
Matrix Bio, which is based in the Purdue Research Park
of West Lafayette, uses technology that company founder Dan Raftery discovered at Purdue University, where he also is a professor of chemistry.
On Tuesday (Oct. 19) the peer-reviewed journal Cancer Research, a
publication of the American Association of Cancer Research, will publish Matrix-Bio's findings, Early Detection of Recurrent Breast Cancer Using Metabolite Profiling. Authored by Raftery with Vincent M. Asiago, Leiddy Z. Alvarado, Naraimhamurthy Shanaiah, G. A. Nagana Gowda, Kwadwo Owusu-Sarfo and Robert Ballas, the study's findings support the
importance of early breast cancer detection and recurrence.
Using metabolite-profiling methods, Matrix-Bio's VeraMarkerTM-BCR blood test correctly predicted a recurrence of breast cancer in 55 percent of the patient survivors an average of 13 months before a clinical diagnosis.
Matrix Bio's cancer monitoring test was developed using a powerful
combination of nuclear magnetic resonance (NMR) and mass spectrometry analytical methods. The test also can be run on a single mass spectrometry platform.
A mass spectrometer in Dan Raftery's research facility collects early
data through blood samples that could help detect cancer or its
recurrence in its earliest stages. The research, conducted at Purdue
University, is being used by Raftery's Purdue Research Park-based
company Matrix-Bio Inc. (Photo provided by Purdue Research Foundation
In the study, the test demonstrated the ability to identify metabolite signals between the recurrence of cancer and no evidence of cancer with a sensitivity of 86 percent and a specificity of 84 percent. This result is two times more sensitive than the current cancer monitoring blood tests CA 27.29 and CA 15-3. In addition, the BCR test opens up a window for second-line therapy by over one year compared to these tests.
"It's important to note that current blood tests do not pick up
recurrence in the 20 percent of breast cancer survivors who do express the protein targeted by these CA tests," Raftery said.
For the more than 2.4 million breast cancer survivors in the United
States and their physicians, the results of Matrix-Bio's research are
extremely promising, according to Raftery, who also is a member of the Purdue Center for Cancer Research and Purdue's Oncological Sciences Center.
"Knowing there's a test that can detect the recurrence of cancer at a
far earlier stage when the cancer is more treatable should provide
tremendous hope to breast cancer survivors and also relieve the
tremendous worry they feel with each visit to their doctor," he said.
"Its accuracy and early stage detection offers a much better window for treatment."
Matrix-Bio's cancer monitoring test is non-invasive, simple to
administer and non-threatening to patients. Blood is drawn from the
patient and sent to a lab for analysis. If the test yields positive
results, the oncologist will order additional tests such as a bone scan, MRI, CAT scan, chest X-ray or liver blood tests to identify and locate the tumor.
Most breast cancers recur in the first three to five years after
treatment following an original diagnosis. During this time women are closely monitored, visiting their oncologist once a quarter for up to three years and once a year after. Breast cancer can come back in the treated breast or near the mastectomy scar or as a distant recurrence somewhere else in the body (metastatic breast cancer). The most common sites of metastasis include the lymph nodes, bones, liver and lungs.
Matrix-Bio's VeraMarker-BCR test will now be clinically validated in a
CLIA licensed laboratory. The company's goal is to make the test
commercially available in the United States by mid- to late-2011.
Dr. Kathy Miller, a medical oncologist and associate professor of
medicine at the Indiana University Melvin and Bren Simon Cancer Center, commented on Matrix-Bio's findings, saying, "Truly early detection of breast cancer has been an elusive goal. This study offers hope for real progress."
Matrix-Bio has received funding from Main Street Venture Fund, Fort
Wayne, Ind., and Purdue University's Emerging Innovations Fund.
Raftery, like Krabbe, has experienced cancer in his own family, which serves as a powerful motivator for his research.
"The existing cancer recurrence tests are inadequate to meet the needs of a large and growing population of breast cancer survivors," he said.
"Making a difference for the estimated 10 million women who are breast cancer survivors globally is the starting point for Matrix-Bio's
VeraMarker Platform in the field of metabolite molecular diagnostics
blood tests for many forms of cancer that affect both women and men."
About Matrix-Bio, Inc.
Founded in 2006, Matrix-Bio, Inc., is an Indiana-based life science
company focused on the development and commercialization of advanced metabolite profiling-based blood tests for early cancer detection, recurrence detection and therapy monitoring that offer greater accuracy, convenience and lower cost than current testing methodologies.
Matrix-Bio's patent-pending metabolite profiling technology has the
potential to be leveraged to other applications for the early detection of disease and medical conditions. For information, visit
May 29, 2015
This RFA requests submissions of project applications for research use of human bio-specimen with longitudinal electronic medical record data. The due date for this Request for Applications is Friday, October 2, 2015. All Purdue full-time faculty members on the West Lafayette campus, regardless of tenure status, are eligible to apply. Samples will be provided free of charge to the qualified awardee(s).Read Full Story
May 15, 2015
The Molecular Therapeutics Program (MTP) released the IDDA 2015 RFA on May 8, 2015. Please see the link for guidelines. If you have any questions, please direct them to Padma Portonovo, who is the Program Manager for the MTP at email@example.com.Read Full Story
May 8, 2015
Purdue University and Indiana University Health Arnett in Lafayette have announced a three-year collaboration agreement to promote human clinical research efforts between the two groups.Read Full Story